DE69101529T2 - Liposom zum Einschliessen von Genen, liposomale Zubereitung und Verfahren zur Herstellung der Zubereitung. - Google Patents

Liposom zum Einschliessen von Genen, liposomale Zubereitung und Verfahren zur Herstellung der Zubereitung.

Info

Publication number
DE69101529T2
DE69101529T2 DE69101529T DE69101529T DE69101529T2 DE 69101529 T2 DE69101529 T2 DE 69101529T2 DE 69101529 T DE69101529 T DE 69101529T DE 69101529 T DE69101529 T DE 69101529T DE 69101529 T2 DE69101529 T2 DE 69101529T2
Authority
DE
Germany
Prior art keywords
preparation
liposome
liposomal
encapsulation
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69101529T
Other languages
English (en)
Other versions
DE69101529D1 (de
Inventor
Kunio Yagi
Hitoshi Noda
Nobuko Ohishi
Masayasu Kurono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VITAMIN KENKYUSHO KK
Original Assignee
VITAMIN KENKYUSHO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VITAMIN KENKYUSHO KK filed Critical VITAMIN KENKYUSHO KK
Publication of DE69101529D1 publication Critical patent/DE69101529D1/de
Application granted granted Critical
Publication of DE69101529T2 publication Critical patent/DE69101529T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
DE69101529T 1990-08-27 1991-08-26 Liposom zum Einschliessen von Genen, liposomale Zubereitung und Verfahren zur Herstellung der Zubereitung. Expired - Fee Related DE69101529T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2222553A JP2958076B2 (ja) 1990-08-27 1990-08-27 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法

Publications (2)

Publication Number Publication Date
DE69101529D1 DE69101529D1 (de) 1994-05-05
DE69101529T2 true DE69101529T2 (de) 1994-11-10

Family

ID=16784255

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69101529T Expired - Fee Related DE69101529T2 (de) 1990-08-27 1991-08-26 Liposom zum Einschliessen von Genen, liposomale Zubereitung und Verfahren zur Herstellung der Zubereitung.

Country Status (5)

Country Link
US (1) US5552157A (de)
EP (1) EP0475178B1 (de)
JP (1) JP2958076B2 (de)
CA (1) CA2050072C (de)
DE (1) DE69101529T2 (de)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM747694A0 (en) * 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
WO1996037194A1 (en) * 1995-05-26 1996-11-28 Somatix Therapy Corporation Delivery vehicles comprising stable lipid/nucleic acid complexes
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
AU6691496A (en) * 1995-08-01 1997-02-26 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
GB9709900D0 (en) 1997-05-15 1997-07-09 Microbiological Res Authority Microencapsulated DNA for vaccination and gene therapy
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
JP2000500744A (ja) 1995-11-09 2000-01-25 マイクロバイオロジカル リサーチ オーソリティー ワクチン接種および遺伝子治療のためのマイクロカプセル化ｄｎａ
JPH09248182A (ja) * 1996-03-15 1997-09-22 Oyo Seikagaku Kenkyusho プラスミド包埋多重膜リポソーム
JP3919227B2 (ja) 1996-05-02 2007-05-23 テルモ株式会社 アミジン誘導体及びそれを構成成分とする薬物担体
CN1138533C (zh) * 1996-09-13 2004-02-18 利普森有限公司 脂质体
US7384923B2 (en) 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
FR2759382A1 (fr) * 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6365590B1 (en) 1998-05-26 2002-04-02 Saint Louis University Compounds, compositions and methods for treating erectile dysfunction
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP2261335B1 (de) * 1998-11-27 2017-06-14 UCB Pharma S.A. Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US6458382B1 (en) * 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
DE60013479T2 (de) 1999-12-13 2005-09-01 Lipoxen Technologies Ltd. Liposomen enthaltend einen komplex aus polyanion und calciumphosphat
KR20090085697A (ko) 2000-02-23 2009-08-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 특이적 동물 단백질
JP2001316297A (ja) * 2000-02-23 2001-11-13 Kaken Pharmaceut Co Ltd 遺伝子包埋リポソーム製剤及びその製法
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
CA2413959C (en) 2000-06-20 2015-07-07 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
JP2004513615A (ja) 2000-06-28 2004-05-13 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002007757A2 (en) 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US20020073441A1 (en) 2000-12-13 2002-06-13 Ross Brian D. Compositions and methods for detecting proteolytic activity
EP1515982A4 (de) 2001-05-09 2005-10-26 Corixa Corp Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
US7776321B2 (en) 2001-09-26 2010-08-17 Mayo Foundation For Medical Education And Research Mutable vaccines
EP1581119B1 (de) 2001-12-17 2013-01-30 Corixa Corporation Zusammensetzungen und verfahren zur behandlung und diagnose von entzündlicher darmerkrankung
AU2003221841A1 (en) 2002-04-03 2003-10-27 Celltech R And D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
EP1519714B1 (de) * 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Verfahren und vorrichtung zur herstellung von liposomen
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
CN101863930A (zh) 2003-01-06 2010-10-20 科里克萨有限公司 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
HUE034760T2 (en) 2003-05-12 2018-02-28 Helion Biotech Aps Masp-2-T binding antibodies
BRPI0411552A (pt) 2003-06-16 2006-08-01 Celltech R & D Inc anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
CA2567597C (en) 2004-05-25 2014-03-18 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
DK2446900T3 (en) 2004-06-10 2017-07-10 Omeros Corp Methods for treating conditions associated with MASP-2-dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US8652477B2 (en) 2009-10-16 2014-02-18 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2005251463A1 (en) 2004-06-14 2005-12-22 Zoser B. Salama Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
JP2008001598A (ja) * 2004-10-12 2008-01-10 Institute Of Physical & Chemical Research アポトーシス誘導物質を含む医薬組成物
WO2006086402A2 (en) 2005-02-08 2006-08-17 Research Development Foundation Compositions and methods related to soluble g-protein coupled receptors(sgpcrs)
EP2386314A1 (de) 2005-03-31 2011-11-16 GlaxoSmithKline Biologicals SA Impfstoff gegen Chlamydieninfektion
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
EP2426141B1 (de) 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Verfahren zur Vorbeugung oder Behandlung einer M-tuberculosis-Infektion
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CA2616877C (en) * 2005-07-27 2014-01-28 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
AU2006318212C1 (en) 2005-11-23 2012-08-30 The Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
EP2441846A3 (de) 2006-01-09 2012-07-25 The Regents Of the University of California Immunstimulierende Kombinationen aus TNFRSF, TLR, NLR, RHR, purinergischem Rezeptor, und Zytokin-Rezeptor-Antagonisten für Impfstoffe und die Tumorimmuntherapie
KR101430773B1 (ko) * 2006-06-30 2014-08-18 홋카이도 시스테무 사이엔스 가부시키가이샤 핵산 도입용 조성물
JP5072275B2 (ja) 2006-07-03 2012-11-14 テルモ株式会社 閉鎖小胞の分離方法、製剤の製造方法および評価方法
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
JP5080779B2 (ja) 2006-10-25 2012-11-21 テルモ株式会社 リポソーム製剤の製造方法
US20100015665A1 (en) * 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
DK2191001T3 (en) 2007-04-09 2016-09-19 Univ Florida RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
EP2185196B1 (de) 2007-08-27 2014-06-11 Longhorn Vaccines & Diagnostics, LLC Immunogene zusammensetzungen und verfahren
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
CA2701168A1 (en) 2007-10-01 2009-07-09 Longhorn Vaccines & Diagnostics, Llc Biological specimen collection and transport system and methods of use
US20110044978A1 (en) * 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
US8753639B2 (en) 2009-03-31 2014-06-17 University Of Washington Through Its Center For Commercialization Compositions and methods for modulating the activity of complement regulatory proteins on target cells
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US8119981B2 (en) * 2009-05-29 2012-02-21 Micromass Uk Limited Mass spectrometer
EP2470560B1 (de) 2009-08-28 2015-06-10 Research Development Foundation Urocortin-2-analoga und ihre verwendung
TW201132353A (en) 2009-12-18 2011-10-01 Amgen Inc WISE binding agents and epitopes
MY156697A (en) 2010-01-27 2016-03-15 Glaxosmithkline Biolog Sa Modified tuberculosis antigens
AU2011242527B2 (en) 2010-04-23 2016-05-19 University Of Florida Research Foundation, Inc. rAAV-guanylate cyclase compositions and methods for treating Leber's congenital amaurosis-1 (LCA1)
EP3444346B1 (de) 2010-04-23 2022-07-27 University of Massachusetts Aav-basierte behandlung von cholesterinerkrankungen
ES2605305T3 (es) 2010-04-23 2017-03-13 University Of Massachusetts Vectores de AAV que se dirigen al SNC y métodos de uso de los mismos
EA202092884A1 (ru) 2010-05-14 2022-01-31 Эмджен Инк. Композиции с высокой концентрацией антител
HUE050909T2 (hu) 2010-05-14 2021-01-28 Univ Oregon Health & Science Paramyxoviridae vírusból izolált heterológ antigént kódoló rekombináns HCMV és RHCMV vektorok és alkalmazásaik
EA201391248A1 (ru) 2011-03-01 2014-05-30 Эмджен Инк. Биспецифические связывающие агенты
EA029956B1 (ru) 2011-03-25 2018-06-29 Эмджен Инк. Кристаллы антител против склеростина и составы на их основе
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
DK3287142T3 (da) 2011-04-08 2021-11-01 Univ Leicester Fremgangsmåder til behandling af tilstande, som er forbundet med masp-2-afhængig komplementaktivering
EP2699680B1 (de) 2011-04-21 2017-12-27 University of Massachusetts Raav-basierte zusammensetzungen und verfahren zur behandlung von alpha-1-anti-trypsin-mangel
CA3131223C (en) 2011-05-04 2024-01-30 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
MX2013013627A (es) 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
MX355816B (es) 2011-08-04 2018-05-02 Amgen Inc Metodo para tratar los defectos de espacio oseo.
EP3712168A3 (de) 2011-12-28 2020-10-14 Amgen Inc. Verfahren zur behandlung von alveolarknochenverlust durch verwendung von anti-sclerostin-antikörpern
CA3207612A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
HUE036930T2 (hu) 2012-04-06 2018-08-28 Omeros Corp Készítmények és eljárások MASP-1 és/vagy MASP-3 gátlására paroxymalis nocturnalis hemoglobinürítés kezelésére
CN104717975A (zh) 2012-06-18 2015-06-17 奥默罗斯公司 用于治疗各种疾病和病症的抑制masp-1和/或masp-2和/或masp-3的组合物和方法
CN104619342A (zh) 2012-07-05 2015-05-13 Ucb医药有限公司 骨疾病的治疗
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
KR20150136061A (ko) 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 대상에 항-액티빈-a 화합물의 투여
EP2983687B1 (de) 2013-03-15 2019-09-04 The Regents of The University of California Peptide mit verminderter toxizität zur stimulation eines cholesterineffluxes
CN105188710A (zh) 2013-03-15 2015-12-23 葛兰素史密丝克莱恩生物有限公司 包含缓冲的氨基烷基氨基葡糖苷磷酸酯衍生物的组合物及其用于增强免疫应答的用途
NZ719476A (en) 2013-10-17 2022-07-29 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
US10280418B2 (en) 2014-03-18 2019-05-07 Univeristy Of Massachusetts RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
US10975391B2 (en) 2014-04-25 2021-04-13 University Of Massachusetts Recombinant AAV vectors useful for reducing immunity against transgene products
EP3200830B1 (de) 2014-10-03 2020-09-09 University of Massachusetts Hocheffiziente bibliotheksidentifizierte aav-vektoren
EP3207150B1 (de) 2014-10-14 2021-04-28 Research Development Foundation Verfahren zur erzeugung von manipulierten enzymen
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
JP6754361B2 (ja) 2014-12-16 2020-09-09 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 若年型バッテン病のための遺伝子療法
AU2015364508A1 (en) 2014-12-18 2017-07-06 Alnylam Pharmaceuticals, Inc. ReversirTM compounds
EP3256140B1 (de) 2015-01-09 2020-04-01 Etubics Corporation Zusammensetzungen für ebola-virus-impfstoff
EP3285788A4 (de) 2015-04-23 2018-12-05 University of Massachusetts Modulation der transgenexpression eines aav-vektors
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
JP2019507582A (ja) 2015-12-04 2019-03-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法用のｓｌｃ４５ａ２ペプチド
US10736960B2 (en) 2016-01-05 2020-08-11 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
US11060088B2 (en) 2016-02-12 2021-07-13 University Of Massachusetts Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
EP3423110B1 (de) 2016-03-03 2021-08-11 University of Massachusetts Geschlossenendige lineare duplex-dna für nichtviralen gentransfer
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3436072A4 (de) 2016-03-31 2019-11-06 Omeros Corporation Verfahren zur hemmung von angiogenese bei einem bedürftigen subjekt
CA3021645A1 (en) 2016-04-29 2017-11-02 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
AU2017315679B2 (en) 2016-08-23 2023-12-14 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
EP3526333A4 (de) 2016-10-13 2020-07-29 University of Massachusetts Aav-capsid-designs
CA3059112A1 (en) 2017-04-05 2018-10-11 University Of Massachusetts Cep290 minigene therapy
WO2018237383A1 (en) 2017-06-23 2018-12-27 The Trustees Of Columbia University In The City Of New York METHODS OF PREVENTING AND TREATING DISEASES CHARACTERIZED BY SYNAPTIC DYSFUNCTION AND NEURODEGENERATION, INCLUDING ALZHEIMER'S DISEASE
TW202402809A (zh) 2017-08-15 2024-01-16 美商歐米諾斯公司 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
EP3768386A4 (de) 2018-03-23 2022-04-13 University of Massachusetts Gentherapeutika zur behandlung von knochenerkrankungen
MX2020010092A (es) 2018-03-30 2020-10-28 Amgen Inc Variantes de anticuerpo c-terminales.
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
KR20210068485A (ko) 2018-09-28 2021-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 노화를 역전시키고 기관 및 조직 재생을 촉진시키기 위한 세포 재프로그래밍
CA3113470A1 (en) 2018-09-28 2020-04-02 President And Fellows Of Harvard College Mutant reverse tetracycline transactivators for expression of genes
WO2020112967A1 (en) 2018-11-29 2020-06-04 University Of Massachusetts Modulation of sptlc1 via recombinant adeno-associated vectors
CA3131023A1 (en) 2019-02-22 2020-08-27 Michael R. Volkert Oxr1 gene therapy
CA3137520A1 (en) 2019-04-24 2020-10-29 University Of Massachusetts Aav capsid chimeric antigen receptors and uses thereof
US20220340643A1 (en) 2019-09-13 2022-10-27 Rutgers, The State University Of New Jersey Aav-compatible laminin-linker polymerization proteins
KR102607199B1 (ko) * 2019-11-22 2023-11-29 주식회사 삼양홀딩스 약물전달용 나노입자 조성물 제조용 키트
JP2023504543A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
WO2021168362A1 (en) 2020-02-21 2021-08-26 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
IL296660A (en) 2020-03-24 2022-11-01 Generation Bio Co Non-viral DNA vectors and their use for therapeutic expression of factor ix
KR20230003478A (ko) 2020-03-24 2023-01-06 제너레이션 바이오 컴퍼니 비-바이러스성 dna 벡터 및 고셰 치료제 발현을 위한 이의 용도
AR122404A1 (es) 2020-03-31 2022-09-07 Univ Massachusetts Variantes de cápside y usos de las mismas
AU2021265832A1 (en) 2020-04-29 2022-11-24 The Broad Institute, Inc. Machine learning accelerated protein engineering through fitness prediction
CA3178726A1 (en) 2020-05-21 2021-11-25 Gregory LIZEE T cell receptors with vgll1 specificity and uses thereof
JP2023539574A (ja) 2020-08-17 2023-09-15 マサチューセッツ インスティテュート オブ テクノロジー Ｓｈａｎｋ３遺伝子治療アプローチ
KR20230117177A (ko) 2020-12-03 2023-08-07 유니버시티 오브 매사추세츠 진행성 골화성 섬유이형성증을 위한 신규 유전자 치료제의개발
CA3212571A1 (en) 2021-03-19 2022-09-22 Trained Therapeutix Discovery, Inc. Compounds for regulating trained immunity, and their methods of use
WO2022232289A1 (en) 2021-04-27 2022-11-03 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
EP4329884A1 (de) 2021-04-27 2024-03-06 Generation Bio Co. Nichtvirale dna-vektoren zur expression von anti-coronavirus-antikörpern und verwendungen davon
IL308282A (en) 2021-05-10 2024-01-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Pharmaceutical compositions for the treatment of neurological diseases
WO2023056329A1 (en) 2021-09-30 2023-04-06 Akouos, Inc. Compositions and methods for treating kcnq4-associated hearing loss
WO2023164545A1 (en) 2022-02-23 2023-08-31 Massachusetts Institute Of Technology Methods for upregulating shank3 expression
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2023196851A1 (en) 2022-04-06 2023-10-12 President And Fellows Of Harvard College Reversing aging of the central nervous system
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55118415A (en) * 1979-02-28 1980-09-11 Pii Papahadojiyopo Dometoriosu Method of encapsulating biologically active substance in lipoid cell
DE3023787A1 (de) * 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
DE3416978A1 (de) * 1983-05-12 1984-12-06 Stauffer Chemical Co., Westport, Conn. Durch liposom vermittelte transformation eukaryotischer zellen
JPH0825869B2 (ja) * 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
JP2923296B2 (ja) * 1988-11-14 1999-07-26 株式会社ビタミン研究所 細胞への遺伝子導入法

Also Published As

Publication number Publication date
EP0475178A1 (de) 1992-03-18
EP0475178B1 (de) 1994-03-30
JPH04108391A (ja) 1992-04-09
DE69101529D1 (de) 1994-05-05
CA2050072C (en) 2000-02-29
US5552157A (en) 1996-09-03
CA2050072A1 (en) 1992-02-28
JP2958076B2 (ja) 1999-10-06

Similar Documents

Publication Publication Date Title
DE69101529T2 (de) Liposom zum Einschliessen von Genen, liposomale Zubereitung und Verfahren zur Herstellung der Zubereitung.
DE3887625D1 (de) Verfahren zur Herstellung von 1,1,1-Trifluorodichlorethan und von 1,1,1,2-Tetrafluorchlorethan.
DE3784841D1 (de) Konfektprodukt und verfahren zur herstellung.
DE3583757D1 (de) Keramisches material und verfahren zu seiner herstellung.
DE3789348D1 (de) Bioverträgliches zusammengesetztes Material und Verfahren zu seiner Herstellung.
DE3784612T2 (de) Thermistor und verfahren zu seiner herstellung.
DE3777931D1 (de) Titandioxydsol und verfahren zur seiner herstellung.
DE3775294D1 (de) Implantatwerkstoff und verfahren zu seiner herstellung.
DE3774333D1 (de) Dauermagnet-material und verfahren zur herstellung.
DE68927949T2 (de) 3,9-Diphosphaspiroundecane und Verfahren zur Herstellung von 3,9-Diphosphaspiroundecanen
DE3681946D1 (de) Zahnfaeuleschutzpraeparate und verfahren zur herstellung derselben.
DE3676655D1 (de) Verbundwerkstoff und verfahren zu seiner herstellung.
DE3784518T3 (de) Medizinisches material und verfahren zur herstellung.
DE3888443D1 (de) Verfahren zur Herstellung von Dihydrochinacridonen, Chinacridonen und Chinacridonchinonen.
DE3783199T2 (de) Verfahren zur herstellung von 4,4' diaminodiphenylmethan und derivaten davon.
DE69611120D1 (de) Verfahren zur Herstellung von "grüner-Tee-Eiern"
DE69313297T2 (de) Benzofuranone, benzodifurantrione und verfahren zur herstellung von benzodifurandionen
DE59501060D1 (de) Verfahren zur Herstellung von 2,5-Dihydrofuran
DE3775012D1 (de) Oberflaechenaktives mittel und verfahren zur dessen herstellung.
DE3762733D1 (de) Keramischer formkoerper und verfahren zu seiner herstellung.
DE69710294T2 (de) Verfahren zur Herstellung von 3,5,5-Trimethyl-Cyclohexa-3-en-1-on
DE59509651D1 (de) Verfahren zur Herstellung von 2,5-Dihydrofuran
DE69007028T2 (de) Verfahren zur Herstellung von 3,4-Epoxybutyrat und Zwischenprodukte dafür.
DE3777245D1 (de) Protein und verfahren zu dessen herstellung.
DE69716203T2 (de) Verfahren zur Herstellung von hochreinem 1,3-Dialkyl-2-imidazolidinon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee